NovAccess Global (XSNX) Stock Price, News & Analysis

Company Overview

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

Key Stats

• Today's Range: $0.0024 to $0.01
• 50-Day Range: $0.0040 to $0.0140
• 52-Week Range: $0.00 to $0.05
• Volume: 16,038 shs
• Average Volume: 7,516 shs
• Market Capitalization: $446,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NovAccess Global Stock Analysis - MarketRank™

NovAccess Global scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NovAccess Global.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NovAccess Global is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NovAccess Global is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the outstanding shares of NovAccess Global have been sold short.

Short Interest Ratio / Days to Cover

NovAccess Global has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NovAccess Global has recently decreased by 97.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NovAccess Global does not currently pay a dividend.

Dividend Growth

NovAccess Global does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the outstanding shares of NovAccess Global have been sold short.

Short Interest Ratio / Days to Cover

NovAccess Global has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NovAccess Global has recently decreased by 97.69%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for NovAccess Global this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NovAccess Global insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.44% of the stock of NovAccess Global is held by insiders.

XSNX Stock Analysis - Frequently Asked Questions

How have XSNX shares performed this year?

NovAccess Global's stock was trading at $0.0201 on January 1st, 2024. Since then, XSNX shares have decreased by 50.2% and is now trading at $0.01.
View the best growth stocks for 2024 here.

How do I buy shares of NovAccess Global?

Shares of XSNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NovAccess Global own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovAccess Global investors own include Co-Diagnostics (CODX), iBio (IBIO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN) and Adamis Pharmaceuticals (ADMP).

Company Calendar

• Today: 11/20/2024
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:XSNX
• CUSIP: N/A
• CIK: 1039466
• Web: www.xsunx.com
• Phone: (213) 642-9268
• Fax: 949-266-5823
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,720,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,723.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.58) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 44,600,000
• Free Float: 43,961,000
• Market Cap: $446,000.00
• Optionable: Not Optionable
• Beta: 1.89